| Cat.No.: | BSM-0389 |
| Product Name: | dBET1 |
| CAS No.: | 1799711-21-9 |
| Figure: |
|
| Product Overview: | A hybrid molecule containing (+)-JQ-1 and thalidomide |
| Description: | dBET1 is a hybrid molecule that combines (+)-JQ1 and thalidomide. The JQ1 portion facilitates binding of dBET1 to the bromodomains of BET family transcriptional activators. The thalidomide moiety drives proteasomal degradation, as phthalimides bind cereblon to create a substrate recognition site for E3 protein ligase complex-mediated ubiquitination. dBET1 induces cereblon-dependent BET protein degradation in vitro (EC50 = 430 nM) and in vivo and delays leukemia progression in mice. |
| Appearance: | A crystalline solid |
| Molecular Weight: | 785.3 |
| Purity: | ≥98% |
| Storage: | -20°C |
| Targets: | BET |
| Molecular Formula: | C38H37ClN8O7S |
| Chemical Name: | (6S)-4-(4-chlorophenyl)-N-[4-[[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]oxy]acetyl]amino]butyl]-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide |
| Warning: | For Research Use Only! Not For Use in Humans. |
USA
Enter your email here to subscribe.
Follow us on
Easy access to products and services you need from our library via powerful searching tools
